Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [18F]AlF-NOTA-SC, [177Lu]Lu-BL02, and [161Tb]Tb-BL02 for Theranostic Development
Muriel Aline Spahn, Tom Van Loy, Christophe M. Deroose, Sofie Celen, Dominique Schols, Guy Bormans, Janke Kleynhans, Frederik Cleeren · 2026
Read Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [18F]AlF-NOTA-SC, [177Lu]Lu-BL02, and [161Tb]Tb-BL02 for Theranostic Development by Muriel Aline Spahn, Tom Van Loy, Christophe M. Deroose, Sofie Celen, Dominique Schols, Guy Bormans, Janke Kleynhans, Frederik Cleeren (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13516207.txt.
Description
Muriel Aline Spahn and seven colleagues evaluate three radioactive tracers aimed at one cancer target in a 2026 study. The target, CXCR4, is a receptor that fuels tumour growth and spread and abounds in blood cancers such as myeloma and lymphoma. Starting from a strong blocking molecule, the team built one imaging agent for PET scans and two therapy agents carrying different radioactive metals, a see-it-then-treat-it pairing called theranostics.
All three products came out highly pure and gripped the receptor tightly. In cell tests they entered only receptor-carrying cells, and the therapy pair killed cells in a dose-dependent way. In mice bearing myeloma grafts, all three reached tumours with low spill into other tissues. Imaging over seven days showed the therapy agent washing out of tumours over time, though.
Catalog record
| CREATOR | Muriel Aline Spahn, Tom Van Loy, Christophe M. Deroose, Sofie Celen, Dominique Schols, Guy Bormans, Janke Kleynhans, Frederik Cleeren |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |